Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported post-hoc analysis of a phase III trial, as well as interim data from a long-term open-label extension study testing Latuda (lurasidone HCI) in children and adolescents with major depressive episodes associated with bipolar I disorder at a scientific meeting in Washington.